Michael J Loeffelholz
Overview
Explore the profile of Michael J Loeffelholz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
1081
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sugden S, Loeffelholz M
Expert Rev Mol Diagn
. 2024 Dec;
:1-10.
PMID: 39688598
Introduction: Rapid and accurate detection of group A (GAS) pharyngitis allows for timely initiation of appropriate antibiotic treatment. This is important to prevent empiric antibiotic overuse while simultaneously lowering the...
2.
Relich R, Van Benten K, Lei G, Robinson C, Carozza M, Sahoo M, et al.
Microbiol Spectr
. 2024 Mar;
12(4):e0390823.
PMID: 38466093
Despite having high analytical sensitivities and specificities, qualitative SARS-CoV-2 nucleic acid amplification tests (NAATs) cannot distinguish infectious from non-infectious virus in clinical samples. In this study, we determined the highest...
3.
Rakeman-Cagno J, Persing D, Loeffelholz M
Expert Rev Mol Diagn
. 2023 Sep;
24(3):147-151.
PMID: 37724428
Introduction: Testing at the point of care (we also refer to the 'point of need'), with rapid, actionable results reported to the patient and provider within hours can impact the...
4.
Ortiz D, Loeffelholz M
Clin Lab Med
. 2023 May;
43(2):155-165.
PMID: 37169439
The practical challenges of point-of-care testing (POCT) include analytical performance and quality compared with testing performed in a central laboratory and higher cost per test compared with laboratory-based tests. These...
5.
Relich R, Loeffelholz M
J Clin Microbiol
. 2022 Dec;
61(1):e0033722.
PMID: 36541768
The classification of viruses remains relevant to several disciplines, including clinical virology. Since the original publication of this review in 2019, many known viruses have undergone taxonomic revisions, and several...
6.
Burns B, Moody D, Tu Z, Nakitandwe J, Brock J, Bosler D, et al.
Microbiol Spectr
. 2022 Oct;
10(6):e0135522.
PMID: 36255326
In 2020, the U.S. Food and Drug Administration (FDA) enabled manufacturers to request emergency use authorization (EUA) to facilitate the rapid authorization of diagnostic (IVD) platforms for the detection of...
7.
Mitchell S, Loeffelholz M
J Clin Microbiol
. 2022 Jun;
60(9):e0050122.
PMID: 35658526
COVID-19 disease lies on a spectrum, ranging from completely asymptomatic to mild disease to severe and critical disease. Studies have shown that prolonged shedding or sporadic detection of SARS-CoV-2 RNA...
8.
Loeffelholz M, Tang Y
Bioanalysis
. 2021 Jul;
13(15):1213-1223.
PMID: 34289741
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent of COVID-19. Testing for SARS-CoV-2 infection is a critical element of the public health response to COVID-19. Point-of-care (POC)...
9.
Rhoads D, Plunkett D, Nakitandwe J, Dempsey A, Tu Z, Procop G, et al.
J Clin Microbiol
. 2021 May;
59(8):e0091321.
PMID: 33972454
No abstract available.
10.
Comparison of the Alere i and BD Veritor Assays for the Rapid Detection of Influenza A and B Viruses
Berry G, Oladipo O, Wittnebert D, Loeffelholz M, Petersen J
J Appl Lab Med
. 2020 Dec;
1(6):735-739.
PMID: 33379826
Background: The use of point-of care testing (POCT) in patient management decisions is becoming increasingly common. Our goal was to evaluate the diagnostic performance of 2 commercially available rapid POCT...